Omega Therapeutics Announces $40 Million Registered Direct Offering of Common Stock
Summary
CAMBRIDGE, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) Omega Therapeutics, Inc. (Nasdaq: OMGA), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenetic mRNA medicines, today announced that it has entered into a securities purchase agreement with investors in a registered direct offering of 6,920,415 shares of common stock at a purchase price of $5.78 per share, resulting in gross proceeds of approximately $40 million. Since the offering was made without an underwriter or a placement agent, Omega will not be paying any underwriting discounts or placement agent fees in connection with the offering.The Shares were offered pursuant to a shelf registration statement on Form S-3 (File No. A final prospectus supplement, which contains additional information relating to the offering, will be filed with the SEC and will be available on the SECs website at www.sec.gov.This press release does not constitute an offer to sell or the solicitation of an offer to buy the Shares, nor shall there be any sale of the Shares in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.Omega Therapeutics, founded by Flagship Pioneering, is a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenetic mRNA medicines. Using a suite of technologies, paired with Omegas process of systematic, rational, and integrative drug design, the OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by returning aberrant gene expression to a normal range without altering native nucleic acid sequences. Omegas modular and programmable mRNA medicines, Omega Epigenomic Controllers, target specific epigenomic loci within insulated genomic domains, EpiZips, from amongst thousands of unique, mapped, and validated genome-wide DNA-sequences, with high specificity to durably tune single or multiple genes to treat and cure diseases through unprecedented precision epigenomic control.